EVOTEC SUBSTANTIALLY REDUCES CARBON EMISSIONS BY JOINING RENEWABLE ENERGY HEATING NETWORK

EVOTEC’S CONNECTION TO THE TOULOUSE ENERGIE DURABLE (“TED”) NETWORK WILL SAVE COSTS AND REDUCE EMISSIONS BY MORE THAN 2,000 TONS OF CO₂E PER YEAR

Hamburg, Germany, 30 November 2022:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company will substantially reduce its carbon emissions by joining the renewable energy heating network Toulouse Energie Durable (“TED”).

Created by EDF subsidiary Dalkia in 2016, the TED network distributes heat energy via a more than 32 km long underground network in the south-east of Toulouse. 70% of the heat energy stems from locally produced renewable and recovered sources. The TED network will deliver Evotec’s Campus Curie with a steady supply of 70 to 90°C hot water, while lowering the operational cost. Further, it makes the Company’s entire Toulouse site, including the future manufacturing facility J.POD® Toulouse, France (EU), fully independent from other heating sources. Evotec is the first fully private partner to join the TED network.

Evotec has signed the Science Based Targets initiative (“SBTi”), committing itself to set targets aligned with the goals of the Paris Agreement. By joining the TED network, Evotec reduces its greenhouse gas emissions by more than 2,000 tons of CO₂ equivalents (“CO₂e”) per year, which equals a 40% reduction of Scope 1 & Scope 2 emissions in 2021 for our Campus Curie and approx. 6% of the Company’s global emissions.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “We are excited to join the TED network in Toulouse. As a signatory of the SBTi, Evotec is constantly looking for ways to reduce its impact on the climate. By joining the TED network, we are taking a significant step towards carbon neutrality while reducing our dependence on other energy sources and reducing our operational cost.”

For further information, please contact the Corporate Communications Team:
Hinnerk Rohwedder, Director of Global Corporate Communications, hinnerk.rohwedder@evotec.com;
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, gabriele.hansen@evotec.com, www.evotec.com
Jean-Luc Moudenc, President of Toulouse Métropole and Mayor of Toulouse said: “With Evotec's connection to the Toulouse heating network, we further develop renewable energies. At a time when Europe is going through a major energy crisis, local authority is taking concrete action here by connecting a private company, demonstrating once again the importance of public authorities and private economic players joining forces in the fight against global warming.”

Valérie Patron, Dalkia’s Regional Director for the South-West region, added: “Dalkia is very proud to have connected the Evotec site to the Toulouse Énergie Durable heating network, thereby enabling a major industrial company in the heart of the city to decarbonise. This connection is a concrete illustration of the collective actions that can be implemented in response to the current energy crisis and the challenges of combating global warming.”

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,500 highly qualified people. The Company’s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.